Reported side effects Mild local irritation or discomfort at the injection site Headache (typically mild and short-lived) Nausea or dizziness in some patients Sweating Mild fever more commonly reported in post-stroke use, generally manageable with standard antipyretics Contraindications Cerebrolysin is not recommended for individuals with: Active epilepsy or seizure disorders Severe renal (kidney) impairment Known hypersensitivity to any component of the formulation Note: A 2023 Cochrane review noted a potentially higher rate of spontaneous adverse events in some stroke trial subgroups
Most peptides degrade rapidly when exposed to stomach acid or digestive enzymes
We recommend storing the vial in its original box or in a dark area of the refrigerator to protect it from light and ensure maximum stability
The DAC modification gives CJC-1295 DAC superior reconstituted solution stability compared to the non-DAC version
No wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts or sesame
PlexusDx provides personalized tirzepatide therapy with clinical guidance to help you manage injection reactions and stay consistent with treatment
